secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K/A
Filed at:   2023-10-27T23:59:59+00:00
Accession:  0000950170-23-056026
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology files Apexigen audited FY22 results; net loss $32M, cash $14.8M
------------------------------------------------------------------------------

- Apexigen FY22 net loss of $32.1M, revenue $0; R&D expense $23.0M, G&A $9.7M.
- Audited balance sheet at Dec 31, 2022: cash and short-term investments $16.8M, accumulated deficit $176.8M.
- Auditors included going-concern doubt; Apexigen had suffered recurring losses and net capital deficiency.
- The amendment provides pro forma combined financials as of June 30, 2023 and for FY22, giving effect to the August 23, 2023 acquisition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023056026/0000950170-23-056026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023056026/pyxs-20230823.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-056026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer